Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Congenital Diaphragmatic Hernia, Pulmona...
Phase NA
Enrollment 10
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to gather information on the safety and effectiveness of a new procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: BALT GoldbBAL2 Detachable Balloon — Latex balloon, with radio-opaque inclusion
  • Device: Catheter System — 100 cm tapered micro-catheter

Primary Outcomes

  • Number of successfully completed FETO procedures (Up to 34 weeks gestation)
  • Operative time (Up to 34 weeks gestation)
  • Frequency of unplanned balloon removal (Up to 34 weeks gestation)
  • Number of incidences of maternal complications (Up to 41 weeks gestation)
  • Number of participants with maternal complications (Up to 41 weeks gestation)
  • Gestational Age at Delivery (Up to 41 weeks gestation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-01
Completion: 2030-11-01
Eligibility
Age: 18 Years – 50 Years
Sex: FEMALE
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rodrigo Ruano
Principal Investigators:
  • Rodrigo Ruano, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) - University of Miami
Contact Information
Study Contact:
Rodrigo A Ruano, MD, Ph.D
305.689.8001
rodrigo.ruano@miami.edu
Rodrigo Ruano, MD, Ph.D
305-689-8001
rodrigo.ruano@miami.edu
University of Miami
Rodrigo Ruano, M.D.
University of Miami
Interventions
  • Device: BALT GoldbBAL2 Detachable Balloon — Latex balloon, with radio-opaque inclusion
  • Device: Catheter System — 100 cm tapered micro-catheter
Study Locations (2 sites)
University of Miami, Miami, Florida 33136 United States
Mayo Clinic, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Singleton pregnancy * Normal fetal karyotype with confirmation by culture results. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is \> 26 weeks. * Isolated Left CDH with liver up * Gestation age at enrollment prior to 29 wks plus 6 days severe pulmonary hypoplasia with ultrasound (US) O/E lung area to head circumference ratio (LHR) \< 25% (measured at 180 to 296 weeks) at the time of surgery; O/E LHR 25% to \<30% (measured at 300 to 316 weeks) at time of surgery. * Gestational age at FETO procedure with O/E LHR \<25% at 27 weeks 0 days to 29 weeks 6 days; with O/E LHR 25% to \<30% at 30 weeks 0 days to 31 weeks 6 days as determined by clinical information (LMP) and evaluation of first ultrasound * Patient meets psychosocial criteria Exclusion Criteria: * Multi-fetal pregnancy * History of natural rubber latex allergy * Preterm labor, cervix shortened (\<15 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa * Psychosocial ineligibility, precluding consent: * Inability to reside within 30 minute drive of our hospital, and inability to comply with the travel for the follow-up requirements of the trial * Patient does not have a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at our institution. * Right sided CDH or bilateral CDH, isolated left sided with O/E LHR ≥30% (measured at 180 to 295 weeks) as determined by ultrasound * Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram at the fetal treatment center. No cases will be removed post hoc if abnormalities are discovered in the course of postoperative monitoring * Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy * History of incompetent cervix with or without cerclage * Placental abnormalities (previa, abruption, accrete) known at time of enrollment * Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy * Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality * Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy
Conditions Gestational Weight Gain, Diet, Healthy, ...
Phase NA
Enrollment 1440
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The overarching research question is: "Does the provision of healthy food (Delivering HOPE) during pregnancy reduce the proportion of women who experience excessive gestational weight gain compared with enhanced standard of care (ESoC)?" To answer this question, the investigators will conduct a large multi-site randomized controlled trial with 1,440 women. Women will be randomized to either the Delivering HOPE arm or the ESoC arm, with approximately 720 participants per arm. Participants randomized to the ESoC arm will receive the standard clinical protocol for nutritional and gestational weight gain counseling recommended for all pregnant women, WIC and SNAP enrollment assistance, referrals to safety net food organizations.Those randomized to the Delivering HOPE arm will be provided the same nutritional and gestational weight gain counseling, WIC and SNAP assistance, and food referrals, as well as a total of $1000/$2000/$3000 (depending on household size) during pregnancy to be used specifically for the purchase of healthy foods recommended in the nutritional counseling. Data for the primary outcome (pre-pregnancy weight and weight at delivery) will be collected from birth records.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Enhanced Standard of Care (ESoC) — Standard recommended nutrition and gestational weight gain counseling; WIC and SNAP enrollment assistance; emergency food referrals
  • Behavioral: Delivering HOPE — ESoC plus healthy food provision

Primary Outcomes

  • Excessive gestational weight gain (EGWG) (Baseline to Post-partum (approx. 40 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-24
Completion: 2029-12-31
Eligibility
Age: 16 Years – 44 Years
Sex: FEMALE
Volunteers: true
Enrollment: 1440 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Arkansas
Collaborators: Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Pearl McElfish, PhD (PRINCIPAL_INVESTIGATOR) - University of Arkansas
  • Lanita White, PharmD (PRINCIPAL_INVESTIGATOR) - Community Health Centers of Arkansas
Contact Information
Study Contact:
Brett Rowland
479-713-8000
mbrowland@uams.edu
Sarah Pollock
479-713-8000
SPollack@uams.edu
Sandra Green
deliveringhope@1stchoice-ar.org
1st Choice Healthcare
Interventions
  • Behavioral: Enhanced Standard of Care (ESoC) — Standard recommended nutrition and gestational weight gain counseling; WIC and SNAP enrollment assistance; emergency food referrals
  • Behavioral: Delivering HOPE — ESoC plus healthy food provision
Study Locations (8 sites)
1st Choice Healthcare, Corning, Arkansas 72422 United States
River Valley Primary Care Services, Lavaca, Arkansas 72941 United States
Olly Neal Community Health Center, Marianna, Arkansas 72360 United States
Boston Mountain Rural Health Center, Marshall, Arkansas 72650 United States
Mainline Health Systems, Monticello, Arkansas 71655 United States
Jefferson Comprehensive Care System, Pine Bluff, Arkansas 71601 United States
Community Clinic, Springdale, Arkansas 72764 United States
East Arkansas Family Health Center, West Memphis, Arkansas 72301 United States
Eligibility Criteria
Inclusion Criteria: * Aged 16-44 years * ≤18 weeks pregnant * Speak English, Spanish, or Marshallese * Valid email address
Conditions High Risk Pregnancy, Remote Patient Moni...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Antenatal nonstress tests (NSTs) are performed to assess fetal health and are used as a cost-effective test that can be widely administered. However, an NST is operator-dependent due to the nature of Doppler ultrasound and is primarily performed in a clinic and hospital setting. The ability to conduct a clinically valuable test at home would address access to care issues faced by numerous women in the United States and reduce the workload on healthcare clinicians facing a shortage of human resources. This pilot study aims to assess the feasibility and acceptability of home NST monitoring in order to determine whether femomTM could be utilized as an adjunct to routine prenatal care. Patients with high risk pregnancies who are recommended to undergo at least once weekly at 32 weeks testing by the obstetrician will be recruited for participation in this study. Participants will be asked to perform three 30 minute monitoring sessions weekly starting at 32 weeks for 6 weeks.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Device: Fetal ECG monitoring — Patients will wear a fetal ECG monitor which they will place on their abdomen

Primary Outcomes

  • Percent of sessions completed (6 weeks)
  • Percentage of interpretable sessions (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-01
Completion: 2027-01-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beth Israel Deaconess Medical Center
Collaborators: Biorithm Pte Ltd
Contact Information
Study Contact:
Ethan Litman, MD, MS
617-677-3000
elitman@bidmc.harvard.edu
Chloe Zera, MD, MPH
617-667-3000
czera@bidmc.harvard.edu
Ethan Litman, MD,MS
617-667-3000
elitman@bidmc.harvard.edu
Beth Israel Deaconess Medical Center
Interventions
  • Device: Fetal ECG monitoring — Patients will wear a fetal ECG monitor which they will place on their abdomen
Study Locations (1 sites)
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Intrauterine pregnancy greater than 32 weeks gestation * Recommended for at least once weekly antenatal fetal testing by their obstetrician * English-speaking Exclusion Criteria: * Under age 18 years of old * Non-english speaking
Conditions Heart Defects, Congenital, Pulmonary Art...
Phase NA
Enrollment 21
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) is associated with considerable morbidity and even mortality. Next to environmental risk factors, the investigators believe that there is an important role of genetic predisposition to develop PAH in CHD. There often is a discrepancy between the severity of PAH and the CHD, where it is useful to screen for PAH gene mutations. The investigators hypothesize that the genotype is partly responsible for the phenotypic variability in patients with congenital shunt lesions, where some develop PAH and others do not. If a genetic predisposition for PAH in CHD could be identified, then genetic screening could be a useful additional tool for early detection of patients at risk of pulmonary vascular disease and PAH development, with new opportunities for prevention or early treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Other: Genetic testing — Genetic testing by DNA sequencing on blood samples after DNA extraction

Primary Outcomes

  • Presence of pathogenic mutations in PAH or ASD genes (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2015-11
Completion: 2027-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 21 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitaire Ziekenhuizen KU Leuven
Principal Investigators:
  • Werner Budts, MD, PhD (PRINCIPAL_INVESTIGATOR) - Universitaire Ziekenhuizen KU Leuven
Contact Information
Study Contact:
Werner Budts, MD, PhD
+32 16 344369
werner.budts@uzleuven.be
Charlien Gabriels, MD
+32 16 341486
charlien.gabriels@uzleuven.be
Werner Budts, MD, PhD
+32 16 344369
werner.budts@uzleuven.be
University Hospitals Leuven
Interventions
  • Other: Genetic testing — Genetic testing by DNA sequencing on blood samples after DNA extraction
Study Locations (1 sites)
University Hospitals Leuven, Leuven, 3000 Belgium
Eligibility Criteria
Inclusion Criteria: * Previous diagnosis of secundum atrial septal defect (ASD) or ventricular septal defect (VSD), with or without repair * Development of PAH, defined as mean PAP ≥ 25 mmHg by right heart catheterization, in combination with a pulmonary wedge pressure of ≤ 15 mmHg and a PVR (pulmonary vascular resistance) of \> 3 Wood units * Preferably, families with congenital shunt lesions (at least three family members affected with ASD or VSD) will be considered for inclusion Exclusion Criteria: * Other congenital heart disease * Mental retardation * Dysmorphic characteristics * Chronic lung disease or total lung capacity \< 80% of predicted value * History of pulmonary embolism
Conditions Pulmonary Hypertension Due to Left Heart...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin. Focusing on dysregulation of the BMPR2-activin pathway, a key regulator of vascular homeostasis, this project uses a multimodal approach combining molecular biology, advanced cardiac imaging, and histology. Its aim is to determine the role of the BMPR2-activin pathway in the development and regression of PH-LHD. We will conduct a prospective observational study with 1-year follow-up in 150 heart failure patients of different etiologies undergoing hemodynamic assessment. Clinical parameters, biomarkers, molecular profiles, and hemodynamic/echocardiographic variables will be analyzed. A nested substudy in 40 heart transplant candidates will include thoracic CT for vascular morphometric analysis and histological correlation in explanted hearts versus healthy controls. We will also assess reversibility of vascular remodeling one year after transplantation. Results may redefine PH-LHD classification, enable phenotypic precision-medicine models, guide targeted therapies such as activin inhibitors, and refine transplant criteria in combined pulmonary hypertension.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Pulmonary vascular resistence (12 months)
  • BMPR2 -activin expression (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-01
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital General Universitario Gregorio Marañon
Collaborators: Fundacion para la Innovacion en Biomedicina (FIBMED), Instituto de Investigación Sanitaria Gregorio Marañón
Principal Investigators:
  • Ana I Fernandez-Avila, PhD (PRINCIPAL_INVESTIGATOR) - Institoto de Investigación Gregorio Marañón
  • Carlos Ortiz, MD, PhD (PRINCIPAL_INVESTIGATOR) - Hospital GU Gregorio Marañón
  • Jorge Martinez-Solano, MD; PhD (PRINCIPAL_INVESTIGATOR) - Hospital GU Gregorio Marañón
Contact Information
Study Contact:
Ana I Fernandez-Avila, PhD
+34650413943
afernandeza.externo@salud.madrid.org
Jorge Martinez-Solano, MD, PhD
jmsolano@salud.madrid.org
Jorge Martinez-Solano, MD, PhD
+3466294110
jmsolano@salud.madrid.org
Hospital GU Gregorio Marañón
Interventions
N/A
Study Locations (1 sites)
Hospital GU Gregorio Marañón, Madrid, Madrid 28007 Spain
Eligibility Criteria
Inclusion Criteria: * Older that 18 years * Heart failled patients with clinical indication for invasive hemodynamic assessment * Written consent Exclusion Criteria: * Refulsl to sign the infomred consent * Presence of iodinated contrast allergy * Ineligibility for HT (for BREATHE-CT substudy)
Conditions Endothelial Function (FMD), Preeclampsia...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Every pregnancy has a major impact on a woman's heart and blood vessels due to changes required by the body to maintain proper blood flow between mother and foetus. When the placenta does not work properly, preeclampsia can occur. An important first symptom is high blood pressure. Women who have experienced preeclampsia are at higher risk of developing blood pressure and heart problems later on. Therefore, it is very important to detect changes in the blood vessel system so that they can be treated promptly and correctly. We aim to do this by using a new, non-invasive eye test that examines the blood vessels of the retina.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Arterial stiffness — Non-invasive test. A blood pressure cuff and tonometer (a type of pen placed on the neck) are used to measure the speed at which a pressure wave propagates from one place to another. Every time the heart contracts, a pressure wave is generated that propagates from the heart to the blood vessels at a certain speed. The stiffer the blood vessels, the faster the wave propagates.
  • Other: Flow-meditad dilatation — This study measures the capacity with which blood vessels expand when we briefly cut off blood flow. The endothelium, the inner layer of blood vessels, regulates this expansion. By ultrasound, we measure the difference in diameter of the elbow artery. To cut off the blood flow, we clamp the forearm with a blood pressure cuff for 5 minutes. When the blood pressure cuff is released, it triggers increased blood flow in the arm, causing the blood vessels to expand. We record this expansion using the above techniques.
  • Other: Dynamic retinal vessel analyzer — Eye imaging measures the capacity with which your blood vessels in the retina can expand in response to a flicker light stimulation.

Primary Outcomes

  • Retinal biomarkers (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-01
Completion: 2025-12-15
Eligibility
Age: 18 Years – 40 Years
Sex: FEMALE
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Antwerp
Contact Information
Study Contact:
Studies cardiologie
+32 3 821 40 74
studies.cardiologie@uza.be
Studies cardiologie
+32 3 821 40 74
studies.cardiologie@uza.be
Antwerp University Hospital
Interventions
  • Other: Arterial stiffness — Non-invasive test. A blood pressure cuff and tonometer (a type of pen placed on the neck) are used to measure the speed at which a pressure wave propagates from one place to another. Every time the heart contracts, a pressure wave is generated that propagates from the heart to the blood vessels at a certain speed. The stiffer the blood vessels, the faster the wave propagates.
  • Other: Flow-meditad dilatation — This study measures the capacity with which blood vessels expand when we briefly cut off blood flow. The endothelium, the inner layer of blood vessels, regulates this expansion. By ultrasound, we measure the difference in diameter of the elbow artery. To cut off the blood flow, we clamp the forearm with a blood pressure cuff for 5 minutes. When the blood pressure cuff is released, it triggers increased blood flow in the arm, causing the blood vessels to expand. We record this expansion using the above techniques.
  • Other: Dynamic retinal vessel analyzer — Eye imaging measures the capacity with which your blood vessels in the retina can expand in response to a flicker light stimulation.
Study Locations (1 sites)
Antwerp University Hospital, Edegem, Antwerp 2650 Belgium
Eligibility Criteria
Inclusion Criteria: * at least 18 years old * willing to undergo vascular assessments * informed consent signed Exclusion Criteria: * Unwilling to provide informed consent * Open-angle glaucoma * Epilepsia * (gestational) Diabetes * Multiple pregnancies * Fetal malformations * Hypercholesterolemia * Kidney disease * Auto-immune disorders * Connective tissue diseases

Change in IOP Fluctuation After DSLT

NCT07428668
Recruiting
Conditions Glaucoma
Phase Not Applicable
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, single-center, single-arm, observational study designed to evaluate the change in diurnal intraocular pressure (IOP) fluctuation following Direct Selective Laser Trabeculoplasty (DSLT) in patients with primary open-angle glaucoma (POAG) who are on 1-3 IOP lowering medications. The study will be conducted at one site and will involve three key visits: a screening visit, a baseline/treatment visit, and a 6-month follow-up visit. During the screening visit, patients will undergo a comprehensive ophthalmic examination, and eligibility will be confirmed. The eye with the higher IOP will be selected if both eyes are eligible. At the baseline visit, diurnal IOP will be recorded at three time points (9am, 12pm, and 4pm) before DSLT is performed. The primary endpoint is the change in diurnal IOP fluctuation 6 months post-treatment. Secondary endpoints include changes in mean diurnal IOP and the proportion of eyes achieving a reduction in IOP fluctuations of ≥1 mmHg. Exploratory endpoints focus on demographic variables associated with IOP fluctuation changes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Voyager DSLT — Voyager DSLT

Primary Outcomes

  • Change in diurnal intraocular pressure (IOP) fluctuation (Measured at baseline and at 6 months post-DSLT treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04-02
Completion: 2027-04-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ophthalmology Associates, Fort Worth
Collaborators: Sengi
Principal Investigators:
  • Brian Flowers, MD (PRINCIPAL_INVESTIGATOR) - Ophthalmology Associates
Contact Information
Study Contact:
Kaitlin Sinclair
(817)332-2020
ksinclair@oafw2020.com
Kaitlin Sinclair
Ophthalmology Associates
Brian Flowers, MD
Ophthalmology Associates
Interventions
  • Device: Voyager DSLT — Voyager DSLT
Study Locations (1 sites)
Ophthalmology Associates, Fort Worth, Texas 76102 United States
Eligibility Criteria
Inclusion Criteria: Visit 1 (Screening) * Subject status as follows: 1. Male or female, 18 years of age or older. 2. Able and willing to attend scheduled follow-up exams for 6 months post-operatively. 3. Able and willing to provide written informed consent on the IRB-approved Informed Consent Form. * Diagnosis of OAG (i.e., primary, pseudoexfoliation, or pigmentary glaucoma) of any severity or OHT in the study eye (i.e., eye to undergo surgery). * IOP-lowering medication regimen in the study eye as follows: a. Zero to three topical IOP-lowering medication classes at the time of Visit 1 (Screening) exam (Note: fixed combination medications \[e.g., Cosopt®, Combigan®, Rocklatan®, Simbrinza®\] count as two medications). * Angle anatomy in the study eye defined as follows: 1. Trabecular meshwork visible on gonioscopy defined by Shaffer grade ≥ 3. 2. Normal anatomy as determined by gonioscopy. 3. Absence of peripheral anterior synechia (PAS), rubeosis or other angle abnormalities that could impair proper DSLT treatment. Visit 2 (Baseline/Treatment) * Medicated mean diurnal IOP (based on 8AM, 10AM and 4PM assessments) of ≥ 16 mmHg and less than or equal to 30 mmHg. * Able and willing to attend scheduled follow-up exams for 6 months post-operatively. * Successful DSLT treatment. Exclusion Criteria: Visit 1 (Screening) * Status in the study eye as follows: 1. Traumatic, malignant, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders. 2. Functionally significant visual field loss, including severe nerve fiber bundle defects. 3. Visual field (mean deviation) worse than -20 dB using 24-2 SITA Standard or equivalent. 4. Prior incisional glaucoma surgery or ALT, or prior MIGS surgery. 5. History of iridotomy, SLT, or MicroPulse Laser Trabeculoplasty (MLT) within the past 2 years. * Unable to provide an adequate and interpretable visual field examination result (i.e., fixation losses, false positives and false negatives must all be less than 33%) in the study eye. * Vertical C/D ratio \> 0.8 in the study eye. * Presence of retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. * Corneal status in the study eye as follows: 1. Any active inflammation or edema (e.g., keratitis, keratoconjunctivitis, keratouveitis). 2. Corneal endothelial dystrophy (e.g., bullous keratopathy, Fuch's dystrophy, guttata). 3. Prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty \[DSAEK\]). 4. Significant scarring or irregularities (including scars from prior corneal surgery such as PKP, RK, etc.) that may interfere with reliability of applanation IOP measurement anticipated corneal surgery of any type (including LASIK, LASEK, PRK, etc.). * Lens status in the study eye: 1. Visually significant cataract expected to require cataract surgery within the next 6 months. 2. Cataract surgery within 24 months prior to Visit 1 (Screening). 3. Anterior chamber intraocular lens (IOL) or implantable contact lens. 4. Congenital or traumatic cataract (except Mittendorf dots). * Choroidal detachment, effusion, choroiditis, neovascularization, or any active choroidopathy. * Retinal or optic nerve disorders in either eye, either degenerative or evolutive, that are not associated with the existing glaucoma condition, including proliferative diabetic retinopathy (mild background diabetic retinopathy permissible), central retinal artery occlusion, central retinal vein occlusion, wet age-related macular degeneration, advanced dry age-related macular degeneration, (e.g., presence of numerous large drusen associated with disturbance to or elevation of the retinal pigment epithelium), significant retinal pigment epithelial changes or optic atrophy. * Other ocular status in the study eye as follows: 1. Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma). 2. History of chronic ocular inflammatory disease or presence of active ocular inflammation (e.g., uveitis, iritis, iridocyclitis, retinitis, ocular herpes). 3. Prior administration of a glaucoma stent (e.g., iStent, Hydrus Microstent). 4. Prior administration of an intracameral implant or drug product (e.g., Travoprost Intraocular Implant, Durysta \[bimatoprost intracameral implant\], Dexycu \[dexamethasone intraocular suspension\]). 5. Any pathology for which, in the investigator's judgment, the following would be either at risk or contraindicated: i. Implantation of iStent infinite. ii. Implantation of a Travoprost Intraocular Implant. iii. Compliance to elements of the study protocol (e.g., ophthalmic examinations, follow-up visits). * Fellow eye status as follows: 1. Best spectacle corrected visual acuity of worse than 20/200. 2. Fellow eye actively enrolled in this trial or any other clinical trial. * Subject status as follows: 1. Breast-feeding, pregnant or planning to become pregnant during the course of the study. 2. Uncontrolled systemic disease (e.g., diabetes, hypertension) that could compromise participation in the study. 3. Immunodeficiency conditions. 4. Use within 30 calendar days of Visit 1 (Screening) or anticipated use during the study of any ophthalmic steroid, or any oral, parenteral, injected, or orally inhaled steroid medication that may cause an increase in IOP. Note: Nasally inhaled steroids are acceptable, as are topical dermal steroids provided they are not applied to the face. 5. Current participation in any study, or participation within 30 days of Visit 1 (Screening). 6. Current (within 30 days) or anticipated use of systemic acetazolamide or methazolamide. 7. Change in an existing chronic systemic therapy that could substantially affect IOP or the study outcomes within 30 days prior to Visit 1 (Screening), or anticipated change during the study. 8. Any ocular disease or condition that, in the opinion of the Investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study. 9. CCT\>620.
Conditions Glaucoma
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

NorMIGS is a non-randomized clinical study of intraocular pressure lowering effect and complications after Preserflo microshunt implantation versus other types of glaucoma surgery. The study is conducted in the Department of Ophthalmology, Oslo University Hospital, Norway.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Procedure: Preserflo microshunt — Implantation of Preserflo microshunt (Santen) to lower intraocular pressure
  • Procedure: Trabeculectomy — Trabeculectomy surgery to lower intraocular pressure
  • Procedure: Other MIGS — Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure

Primary Outcomes

  • Intraocular pressure (8 weeks after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-04-22
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oslo University Hospital
Principal Investigators:
  • Olav Kristianslund, MD PhD (PRINCIPAL_INVESTIGATOR) - Department of Ophthalmology, Oslo University Hospital
Contact Information
Study Contact:
Olav Kristianslund, MD PhD
+4722118545
olakri@ous-hf.no
Olav Kristianslund
Department of Ophthalmology, Oslo University Hospital
Interventions
  • Procedure: Preserflo microshunt — Implantation of Preserflo microshunt (Santen) to lower intraocular pressure
  • Procedure: Trabeculectomy — Trabeculectomy surgery to lower intraocular pressure
  • Procedure: Other MIGS — Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure
Study Locations (1 sites)
Department of Ophthalmology, Oslo University Hospital, Oslo, 1163 Norway
Eligibility Criteria
Inclusion Criteria: * Patients must be 18 years or older at the time of signing the informed consent form. There is no upper age limit. * Scheduled for implantation of Preserflo microshunt, trabeculectomy or other types of MIGS * Ability to cooperate fairly well during the examinations * Willing to participate in the study and capable of providing informed consent Exclusion Criteria: \- High intraocular pressure due to increased episcleral venous pressure, hemorrhagic glaucoma, traumatic glaucoma or uveitis glaucoma
Conditions Breast Cancer
Phase NA
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This pilot study will examine the impact of pre-operative Medical Reiki© on the psychosocial well-being and recovery of underserved women undergoing breast cancer surgery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Other: Medical Reiki — Reiki is a form of energy therapy involving the facilitation of healing through the manipulation of biofields utilizing light touch. It is a process of targeting the energy fields around the patient's body is believed to stimulate the patient's natural ability to heal itself.
  • Other: Sham Reiki — Sham Reiki involves a non-Reiki healer who mimics the treatment of a Reiki healer. Sham Reiki providers will be medical students who are not interested and without prior knowledge or experience with Reiki Medicine.The medical students will not have any prior experience in Reiki healing or associated energy healing modalities. It is better for this project if the medical student has no interest so there is true placebo effect being monitored.

Primary Outcomes

  • Feasibility based on Number Screened for Inclusion (2 months)
  • Feasibility - Percentage of Patients who met Inclusion Criteria (2 months)
  • Feasibility - Percentage of Patients who Assented for Informed Consent (2 months)
  • Feasibility - Percentage of Patients who Completed the Informed Consent Procedure (2 months)
  • Feasibility - Percentage of Patients who Agreed and Refused to Participate (2 months)
  • Feasibility - Percentage of Patients who Completed Baseline Assessments (2 months)
  • Feasibility - Percentage of Patients who were Randomly Allocated as per allocation list to Treatment Arm (2 months)
  • Feasibility - Percentage of Patients who Received Intended Intervention (2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-11-09
Completion: 2026-11
Eligibility
Age: 18 Years – 99 Years
Sex: FEMALE
Volunteers: false
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Albert Einstein College of Medicine
Collaborators: Medical Reiki Works, Inc
Principal Investigators:
  • Alyson Moadel, PhD (PRINCIPAL_INVESTIGATOR) - Albert Einstein College of Medicine
Contact Information
Study Contact:
Alyson Moadel, PhD
(718)430-2696
Alyson.moadel-robblee@einsteinmed.edu
Camille Garrett, MPH
818 903 1451
camille.garrett@einsteinmed.edu
Alyson Moadel, PhD
718-430-2696
alyson.moadel-robblee@einsteinmed.edu
Montefiore Medical Center
Interventions
  • Other: Medical Reiki — Reiki is a form of energy therapy involving the facilitation of healing through the manipulation of biofields utilizing light touch. It is a process of targeting the energy fields around the patient's body is believed to stimulate the patient's natural ability to heal itself.
  • Other: Sham Reiki — Sham Reiki involves a non-Reiki healer who mimics the treatment of a Reiki healer. Sham Reiki providers will be medical students who are not interested and without prior knowledge or experience with Reiki Medicine.The medical students will not have any prior experience in Reiki healing or associated energy healing modalities. It is better for this project if the medical student has no interest so there is true placebo effect being monitored.
Study Locations (1 sites)
Montefiore Medical Center, The Bronx, New York 10461 United States
Eligibility Criteria
Inclusion Criteria: * Ages 18-99 * Breast Cancer Diagnosis Stage 0-III * Undergoing unilateral or bilateral mastectomy (with or without reconstruction) within 2 weeks of recruitment * English Speaking * From within 50 miles of Bronx County, NY Exclusion Criteria: * Current, uncontrolled psychiatric co-morbidities * Pregnant women
Conditions Breast Neoplasms, Liver Neoplasms, Metas...
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-center, parallel-controlled clinical study designed to evaluate the safety, efficacy and impact on systemic anti-tumor immunity of a multi-mode integrated ablation system for the treatment of breast cancer liver metastases.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Multi-mode tumor treatment system — All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. The treatment procedure includes: rapid freezing of the tumor tissue to form an ice ball extending 5mm beyond the lesion, maintaining this state for 5 minutes, followed by thawing and rewarming; subsequently, RFA is performed to ensure complete ablation, with the ablation zone including a safety margin of 5-10mm around the tumor.
  • Device: Radiofrequency ablation therapeutic apparatus — All subjects are treated using the radiofrequency ablation therapeutic apparatus (MedSphere International (Shanghai) Co., Ltd.), with the treatment procedure conducted according to the preset power and time parameters to ensure a safety margin of 5-10mm.

Primary Outcomes

  • Anti-tumor immune response (max 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-09
Completion: 2027-12
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ruijin Hospital
Contact Information
Study Contact:
Chief Physician of Interventional Radiology Department
021-64370045
dxy10456@rjh.com.cn
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Interventions
  • Device: Multi-mode tumor treatment system — All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. The treatment procedure includes: rapid freezing of the tumor tissue to form an ice ball extending 5mm beyond the lesion, maintaining this state for 5 minutes, followed by thawing and rewarming; subsequently, RFA is performed to ensure complete ablation, with the ablation zone including a safety margin of 5-10mm around the tumor.
  • Device: Radiofrequency ablation therapeutic apparatus — All subjects are treated using the radiofrequency ablation therapeutic apparatus (MedSphere International (Shanghai) Co., Ltd.), with the treatment procedure conducted according to the preset power and time parameters to ensure a safety margin of 5-10mm.
Study Locations (1 sites)
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years, female gender; 2. Pathologically confirmed breast cancer liver metastases, in patients who are unable to tolerate or refuse surgical resection; 3. The number of lesions ≤ 3, with any single lesion diameter ≤ 4cm; 4. At least an interval of 1 month since the last local treatment; 5. Child-Pugh class A or B; 6. ECOG PS score ≤2, with an expected survival of \>3 months. Exclusion Criteria: 1. Liver function Child-Pugh class C; 2. Systemic widespread metastasis, with an expected survival of \< 3 months; 3. History of esophageal (gastric fundus) variceal bleeding within the past month; 4. Dysfunction or failure of vital organs; 5. Presence of an active infection; 6. Irreparable coagulation abnormality; 7. Refractory massive ascites, pleural effusion or cachexia; 8. Pregnancy, altered consciousness or patients unable to cooperate with treatment; 9. Previously participated in other clinical studies and still within the follow-up period; 10. Any other factors deemed inappropriate for inclusion or that may affect the patient's participation in the study, as determined by the investigator.
Conditions Breast Cancer, Shoulder Dysfunction
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effectiveness of a physiotherapy program incorporating visual biofeedback compared to a conventional physiotherapy program in improving shoulder function in women following breast cancer surgery. Breast cancer survivors frequently experience shoulder dysfunction, including reduced range of motion, decreased strength, altered neuromuscular activity, and impaired scapulohumeral control. While conventional physiotherapy is effective, there is growing interest in interventions targeting motor control and neuromuscular coordination through biofeedback strategies. Participants will be randomly assigned to either a control group receiving conventional physiotherapy or an experimental group receiving the same program supplemented with visual biofeedback using the MotionGuidance system. Outcomes will include shoulder strength, range of motion, functional performance, electromyographic activity, and muscle oxygen saturation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Experimental Group: Physiotherapy + Visual Biofeedback — Participants will receive a structured physiotherapy program combined with visual biofeedback using the MotionGuidance system. The intervention includes guided exercises with laser-based visual feedback to improve motor control and movement accuracy.

Primary Outcomes

  • Shoulder Strength (kg) (Baseline and 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-14
Completion: 2026-05-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Extremadura
Contact Information
Study Contact:
Mª Dolores MDAA Apolo-Arenas, PhD
924489180
mdapolo@unex.es
Mª Dolores MD Apolo-Arenas, PhD
924489180
mdapolo@unex.es
Facultad de Mecina y Ciencias de la Salud
Alejandro ACP Caña-Pino, PhD
Facultad de Mecina y Ciencias de la Salud
Interventions
  • Procedure: Experimental Group: Physiotherapy + Visual Biofeedback — Participants will receive a structured physiotherapy program combined with visual biofeedback using the MotionGuidance system. The intervention includes guided exercises with laser-based visual feedback to improve motor control and movement accuracy.
Study Locations (1 sites)
Facultad de Mecina y Ciencias de la Salud, Badajoz, Badajoz 06006 Spain
Eligibility Criteria
Inclusion Criteria: * Women aged 18 years or older * History of breast cancer surgery (mastectomy or breast-conserving surgery within the last 6 months) * Presence of shoulder pain, reduced range of motion, strength deficit, or functional limitation * Ability to understand and follow study instructions Exclusion Criteria: * Presence of metastasis * Post-surgical complications contraindicating exercise * Severe lymphedema (Stage III or IV) * Neurological disorders affecting the upper limb * Severe musculoskeletal shoulder conditions unrelated to breast cancer * Participation in other rehabilitation programs
Conditions Breast Cancer, Artificial Intelligence, ...
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Mammography is the most common method for breast imaging, and it provides information for model building and analysis. Radiomics applied to mammography has the potential to revolutionize clinical decision-making by providing valuable insights into risk assessment and disease detection. Despite this, the influence of imaging parameters and clinical and biological factors on radiological texture features remains poorly understood. There is a pressing need to overcome the obstacle of system-inherent effects on mammographic images to facilitate the translation of radiological texture features into routine clinical practice by enabling reliable and robust AI-based or AI-aided decision-making. Furthermore, understanding the relationship between imaging parameters, textural features, and clinical and biological information supports the clinical use of AI. The objective of this study is to evaluate AI methods for clinical practice and to study how it relates to clinical factors and biological features.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: Single

Interventions / Regimen

  • Device: AI tool — Both the arms will undergo the use of "AI tool" developed in the group. The tool will be trained to detect outcomes.

Primary Outcomes

  • Mammographic texture features (Through study completion, an average of 5 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-17
Completion: 2038-12-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tampere University Hospital
Collaborators: Tampere University, Kuopio University Hospital, University of Eastern Finland, University of Turku, University of Oulu
Contact Information
Study Contact:
Otso Arponen, MD, PhD
+3583311611
otso.arponen@tuni.fi
Interventions
  • Device: AI tool — Both the arms will undergo the use of "AI tool" developed in the group. The tool will be trained to detect outcomes.
Study Locations (1 sites)
Wellbeing Services County of Pirkanmaa, Tampere, Finland
Eligibility Criteria
Inclusion Criteria: * Candidate is a biological female aged 18 years or above; * Candidate is willing and able to give informed consent and gives their written consent for the participation in the study; * There is a clinical indication for a uni- or bilateral mastectomy Exclusion Criteria: * Candidate lacks the capacity to provide informed consent; * Candidate has breast implants